Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own0.30% Shs Outstand41.53M Perf Week-9.91%
Market Cap2.26B Forward P/E- EPS next Y-2.82 Insider Trans-37.10% Shs Float33.67M Perf Month-9.41%
Income-59.40M PEG- EPS next Q-0.49 Inst Own90.40% Short Float9.68% Perf Quarter-15.99%
Sales26.80M P/S84.42 EPS this Y-192.40% Inst Trans1.86% Short Ratio12.46 Perf Half Y11.53%
Book/sh9.46 P/B5.76 EPS next Y- ROA-16.90% Target Price77.56 Perf Year38.80%
Cash/sh9.13 P/C5.97 EPS next 5Y- ROE-19.60% 52W Range35.55 - 67.79 Perf YTD29.41%
Dividend- P/FCF- EPS past 5Y- ROI-20.60% 52W High-19.63% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin- 52W Low53.25% ATR3.67
Employees102 Current Ratio8.60 Sales Q/Q196.80% Oper. Margin- RSI (14)44.68 Volatility6.69% 6.41%
OptionableYes Debt/Eq0.00 EPS Q/Q21.10% Profit Margin- Rel Volume1.83 Prev Close57.30
ShortableYes LT Debt/Eq0.00 EarningsNov 08 Payout- Avg Volume261.61K Price54.48
Recom1.60 SMA20-5.76% SMA50-3.27% SMA2000.55% Volume479,999 Change-4.92%
Oct-01-18Initiated Cantor Fitzgerald Overweight $90
Sep-28-18Initiated Citigroup Buy $90
Sep-10-18Initiated Morgan Stanley Overweight $72
Jul-10-18Initiated BofA/Merrill Buy $71
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Dec-11-18 08:30AM  MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients GlobeNewswire
Dec-05-18 04:01PM  MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-18 08:38AM  Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Nov-28-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy Fundamental Analysis, Key Performance Indications GlobeNewswire +6.18%
Nov-12-18 07:30AM  MyoKardia Presents Preclinical Evidence of Mavacamtens Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-08-18 05:34PM  Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals +6.99%
Nov-07-18 08:50PM  MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:48PM  MyoKardia: 3Q Earnings Snapshot Associated Press
04:38PM  All this 500,000-square-foot Berkeley biotech project needs is a developer American City Business Journals
04:30PM  MyoKardia Reports Third Quarter 2018 Financial Results GlobeNewswire
08:01AM  MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 08:00AM  MyoKardia to Present Clinical Evidence of Mavacamtens Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions GlobeNewswire
08:00AM  MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions GlobeNewswire
Nov-01-18 10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals
Oct-31-18 10:10AM  Bears Are Doing an EKG Test on MyoKardia TheStreet.com
Oct-30-18 07:30AM  MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day GlobeNewswire
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals -5.69%
Oct-25-18 10:34AM  MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up? Zacks +6.00%
12:00AM  MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe GlobeNewswire
Oct-24-18 04:30PM  MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy GlobeNewswire -6.60%
Oct-22-18 08:30AM  MyoKardia to Host R&D Day on October 30, 2018 GlobeNewswire
Oct-19-18 08:30AM  Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
08:01AM  MyoKardia to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
Aug-29-18 04:01PM  MyoKardia to Present at Two Upcoming Investor Conferences in September GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-08-18 08:05PM  MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:02PM  MyoKardia: 2Q Earnings Snapshot Associated Press
04:02PM  MyoKardia Reports Second Quarter 2018 Financial Results GlobeNewswire
03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals
02:30PM  MyoKardia, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 04:01PM  MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference GlobeNewswire
Aug-01-18 04:30PM  MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018 GlobeNewswire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE +5.17%
Jul-10-18 02:06PM  BofA Revives Myokardia With New Buy Rating Benzinga
Jul-03-18 08:10AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and MyoKardia ACCESSWIRE
Jun-26-18 08:30AM  MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
Jun-06-18 08:30AM  Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-22-18 08:05PM  MyoKardia Announces Pricing of Public Offering of Common Stock GlobeNewswire
May-21-18 04:01PM  MyoKardia Announces Proposed Public Offering of Common Stock GlobeNewswire -6.57%
07:30AM  MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
May-18-18 07:07PM  Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55? Simply Wall St.
May-17-18 01:39PM  Inspire Awards 2018: Mary Cranston on why women need to push back on stereotypes about leadership American City Business Journals
May-10-18 04:30PM  MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
08:30AM  MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
May-09-18 02:35PM  Edited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents -7.42%
May-08-18 05:44PM  MyoKardia: 1Q Earnings Snapshot Associated Press
04:01PM  MyoKardia Reports First Quarter 2018 Financial Results GlobeNewswire
May-03-18 04:01PM  MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018 GlobeNewswire
Apr-09-18 08:10AM  New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-04-18 08:30AM  MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer GlobeNewswire
Apr-02-18 08:30AM  MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
Mar-16-18 08:15AM  Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-09-18 09:50AM  Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 05:28PM  MyoKardia reports 4Q loss Associated Press
04:03PM  MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
04:02PM  MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
01:15PM  MyoKardia, Inc. to Host Earnings Call ACCESSWIRE
09:34AM  Earnings Preview For MyoKardia Benzinga
Mar-06-18 08:00AM  MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 04:30PM  MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018 GlobeNewswire
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Endocyte and MyoKardia ACCESSWIRE -5.56%
Feb-14-18 04:30PM  MyoKardia to Present at the RBC Capital Markets 2018 Healthcare Conference GlobeNewswire +6.53%
08:30AM  MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients GlobeNewswire
Jan-19-18 08:30AM  MyoKardia Announces Appointment of Cynthia Ladd as General Counsel GlobeNewswire
Jan-16-18 03:50PM  Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Jan-10-18 12:08PM  4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE) SmarterAnalyst
Jan-03-18 04:30PM  MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-17 11:51AM  ETFs with exposure to MyoKardia, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:21AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-11-17 07:25AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017 Capital Cube
Nov-15-17 08:00AM  Preclinical Studies with MyoKardias Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance GlobeNewswire
Nov-13-17 07:15PM  MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor GlobeNewswire
Nov-08-17 09:44AM  MyoKardia, Inc. Value Analysis (NASDAQ:MYOK) : November 8, 2017 Capital Cube
Nov-07-17 12:48PM  Myokardia Inc (MYOK) Q3:17 Update At First Glance SmarterAnalyst
Nov-06-17 07:17AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017 Capital Cube
Nov-02-17 05:54PM  MyoKardia reports 3Q loss Associated Press
04:02PM  MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress GlobeNewswire
Nov-01-17 08:00AM  MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions GlobeNewswire
Oct-31-17 08:00AM  MyoKardia to Present at Two Upcoming Investor Conferences in November GlobeNewswire
Oct-26-17 08:00AM  MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017 GlobeNewswire
Oct-12-17 08:24AM  MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017 Capital Cube
Oct-10-17 11:39AM  ETFs with exposure to MyoKardia, Inc. : October 10, 2017 Capital Cube
Oct-09-17 09:51AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 Capital Cube
Oct-02-17 10:50AM  Best Sector ETF of Q3 and its Top-Performing Stocks Zacks
Sep-27-17 07:30AM  MyoKardia Provides Update on MYK-491 Clinical Progress GlobeNewswire
Sep-25-17 07:01PM  Cramer's lightning round: Why I can't go down the path of... CNBC Videos -5.20%
06:48PM  Cramer's lightning round: Why I can't go down the path of US Steel CNBC
Sep-18-17 04:45PM  MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment TheStreet.com
12:45PM  MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of Americas 21st Annual Scientific Meeting GlobeNewswire
Aug-30-17 08:00AM  MyoKardia to Present at Two Upcoming Investor Conferences in September GlobeNewswire
Aug-16-17 08:58AM  MyoKardia (MYOK) Looks Good: Stock Adds 6.32% in Session Zacks +5.69%
Aug-14-17 11:14AM  MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Aug-10-17 08:00AM  MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-09-17 07:30AM  [$$] Zinsli's Take: Biotech's Saviors Keep Up VCs' Hopes The Wall Street Journal
Aug-08-17 08:16PM  MyoKardia Announces Pricing of Public Offering of Common Stock GlobeNewswire +15.10%
04:21PM  Edited Transcript of MYOK earnings conference call or presentation 7-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
04:12PM  MyoKardia Inc. Is on the Rise Again Today -- Here's Why Motley Fool
Aug-07-17 11:59PM  MyoKardia reports 2Q loss Associated Press +83.38%
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications; and a collaboration with 23andMe, Inc. to advance research for patients with hypertrophic cardiomyopathy. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee JuneSee RemarksDec 03Option Exercise11.955,00059,7505,770Dec 06 08:13 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 05Option Exercise1.513,0004,52078,087Nov 06 07:32 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 05Sale56.573,000169,71675,087Nov 06 07:32 PM
Bauer JakeChief Business OfficerNov 02Sale55.4597854,23059,900Nov 06 07:30 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Option Exercise1.513,0004,52077,949Oct 05 09:13 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Sale58.193,000174,57874,949Oct 05 09:13 PM
Lee JuneSee RemarksSep 21Option Exercise11.955,00059,7505,426Sep 24 08:26 PM
Lee JuneSee RemarksSep 21Sale63.135,000315,652426Sep 24 08:26 PM
Semigran MarcChief Medical OfficerSep 05Option Exercise15.953,60057,4203,600Sep 06 05:00 PM
Semigran MarcChief Medical OfficerSep 05Sale60.003,600216,0000Sep 06 05:00 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 04Option Exercise1.513,0004,52077,949Sep 06 04:59 PM
Semigran MarcChief Medical OfficerSep 04Option Exercise15.9541,400660,33041,400Sep 06 05:00 PM
Semigran MarcChief Medical OfficerSep 04Sale59.4941,4002,463,0060Sep 06 05:00 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 04Sale59.333,000178,00474,949Sep 06 04:59 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 06Option Exercise1.513,0004,52077,949Aug 08 06:54 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 06Sale57.473,000172,41074,949Aug 08 06:54 PM
Bauer JakeChief Business OfficerJul 23Option Exercise13.907,500104,25068,106Jul 25 04:17 PM
Bauer JakeChief Business OfficerJul 23Sale56.887,500426,56560,606Jul 25 04:17 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 05Option Exercise1.513,0004,52077,949Jul 06 06:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 05Sale53.133,000159,37974,949Jul 06 06:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 04Option Exercise1.513,0004,52077,949Jun 06 07:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 04Sale46.953,000140,86474,949Jun 06 07:34 PM
Sanofi10% OwnerMay 25Buy49.00150,0007,350,0004,168,899May 29 04:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Option Exercise1.512,9814,49277,949May 07 09:47 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Sale47.573,000142,70074,949May 07 09:47 PM
Bauer JakeChief Business OfficerMay 03Sale48.951,51974,35560,606May 07 05:43 PM
Bauer JakeSee RemarksApr 11Option Exercise12.255,00061,25066,777Apr 12 08:32 PM
Bauer JakeSee RemarksApr 11Sale50.005,000250,00061,777Apr 12 08:32 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Option Exercise1.513,0004,52077,390Apr 05 07:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Sale47.953,000143,86374,390Apr 05 07:48 PM
Bauer JakeSee RemarksMar 26Option Exercise9.081641,48961,941Mar 28 04:08 PM
Bauer JakeSee RemarksMar 26Sale50.951648,35661,777Mar 28 04:08 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 05Option Exercise1.513,0004,52077,390Mar 07 04:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 05Sale61.073,000183,20574,390Mar 07 04:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 26Option Exercise1.515,0007,53479,390Feb 28 07:29 PM
Bauer JakeSee RemarksFeb 26Option Exercise9.085,10246,32666,879Feb 28 07:34 PM
Bauer JakeSee RemarksFeb 26Sale60.005,102306,12061,777Feb 28 07:34 PM
Lambing JosephSee RemarksFeb 26Sale60.002,300138,00093,546Feb 28 07:31 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 26Sale60.005,000300,00074,390Feb 28 07:29 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 05Option Exercise1.513,0004,52077,390Feb 07 06:37 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 05Sale51.053,000153,13974,390Feb 07 06:37 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 12Option Exercise1.515,0007,534514,117Jan 16 06:47 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 12Sale50.005,000250,000509,117Jan 16 06:47 PM
Lambing JosephSee RemarksJan 12Sale50.005,000250,00095,846Jan 16 06:46 PM
Bauer JakeSee RemarksJan 09Sale45.005,000225,00056,777Jan 10 04:45 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 04Option Exercise1.513,0004,520512,117Jan 05 05:27 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 04Sale41.703,000125,103509,117Jan 05 05:27 PM
STARR KEVIN PDirectorJan 03Sale42.00816,32634,285,774680,272Jan 05 04:30 PM
Third Rock Ventures III, L.P.10% OwnerJan 03Sale42.00816,32634,285,774680,272Jan 05 04:30 PM
Bauer JakeSee RemarksJan 02Sale42.895,000214,46661,777Jan 03 08:06 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 21Option Exercise1.513,0004,520512,117Dec 26 04:46 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 21Sale41.093,000123,268509,117Dec 26 04:46 PM